Hostname: page-component-74656f9884-c52kr Total loading time: 0 Render date: 2026-11-09T00:31:53.735Z Has data issue: false hasContentIssue false
  • English
  • Français

Special GMO Symposium

Published online by Cambridge University Press:  20 July 2007

Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Information

Type
Special GMO Symposium
Information
World Trade Review , Volume 6 , Issue 2 , July 2007 , pp. 213
Copyright
Copyright © Tomer Broude 2007

The following articles were first presented in Jerusalem on 21 June 2006, at a Roundtable entitled ‘Understanding the WTO Panel Report in EC-Biotech’.Footnote * The purpose of the Roundtable was to discuss the critical aspects the EC-Biotech Panel's Interim Report, which had been publicly available (though not through the Panel's own action) for several months. The EC-Biotech Panel Report was subsequently circulated on 29 September 2006 and adopted, without appeal, by the Dispute Settlement Body on 21 November 2006.

The EC-Biotech dispute concerns a number of highly sensitive issues related to the balance between international trade, public health, environmental protection, national regulatory authority, and science. The Panel Report extensively addresses many questions of WTO law over more than 1000 pages. The following articles do not purport to cover all the questions raised by the Panel Report, but merely to explain and critique the Panel's approach to some of the most central ones.

References

* The Roundtable was organized by Tomer Broude of the Hebrew University of Jerusalem with the generous funding of the Davis Institute of International Relations (Dir. Prof. Alfred Tovias) and the International Law Forum of the Faculty of Law (Dir. Prof. Moshe Hirsch). Ms Anat Kleiman is thanked for her administrative assistance.